Meeting
2022 ASCO Gastrointestinal Cancers Symposium
A pilot study of liposomal irinotecan plus 5-FU/ LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy.
Authors
Patrick Grierson
Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
Patrick Grierson , Rama Suresh , Benjamin R. Tan Jr., Katrina Sophia Pedersen , Manik A. Amin , Haeseong Park , Nikolaos Trikalinos , Jingxia Liu , Kian-Huat Lim , Andrea wang-gillam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03883919
DOI
10.1200/JCO.2022.40.4_suppl.566
Abstract #
566
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Early tumor shrinkage as a predictor of favorable outcomes in patients (pts) with advanced pancreatic cancer treated with FOLFIRINOX.
First Author: Yasuhiro Kaga
Poster
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
First Author: Aaron Ciner
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of the third-line chemotherapy in patients with advanced pancreatic cancer.
First Author: Bomi Kim
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Serum vitamin D3 levels and overall survival (OS) in patients (pts) with advanced biliary tract cancer (BTC): Analysis of the NIFTY trial cohort.
First Author: So Heun Lee